Shots:

• The approval is based on P-III DAPA-HF study involves assessing of Forxiga (10mg) + SOC vs PBO +SOC in 4744 patients with heart failure and reduced ejection fraction (LVEF ≤ 40%) with/out T2D
• Results: reduction in risk of the composite outcome by 26%- with both components of the 1EPs (first occurrence of a worsening HF event or CV death) contributed benefit to the overall effect.
• Forxiga is the first SGLT2 inhibitor approved in the EU for HFrEF in adult patients with/out T2D. The therapy is currently being evaluated for HFpEF in P-III DELIVER study with its anticipated results in H2’21

  Ref: AstraZeneca | Image: New Europe